The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Yue, Fu, Yucheng, Zeng, Yue, Liu, Xiaohan, Peng, Yurong, Hu, Chunhong, Deng, Chao, Qiu, Zhenhua, Zou, Jian, Liu, Yuxuan, Wu, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900392/
https://www.ncbi.nlm.nih.gov/pubmed/35255999
http://dx.doi.org/10.1186/s40364-022-00355-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900392/
https://www.ncbi.nlm.nih.gov/pubmed/35255999
http://dx.doi.org/10.1186/s40364-022-00355-7

Ejemplares similares